| Literature DB >> 22542810 |
Toshiyuki Okazaki1, Teruyoshi Kageji, Kazuyuki Kuwayama, Keiko T Kitazato, Hideo Mure, Keijiro Hara, Ryoma Morigaki, Yoshifumi Mizobuchi, Kazuhito Matsuzaki, Shinji Nagahiro.
Abstract
Interferon-beta (IFN-β) is reported to augment anti-tumor effects by temozolomide in glioblastoma via down-regulation of MGMT. Promyelocytic leukemia (PML), a gene induced by IFN-β, is a tumor suppressor. Here, we report for the first time that in combination therapy, an IFN-β-induced increase in endogenous PML contributes to anti-tumor effects in p53 wild- and mutant glioma cells in a xenograft mice model. The increased PML promoted the accumulation of p73, a structural and functional homolog of p53, to fuse the coactivator Yes-associated-protein in the PML nuclear bodies. The adjuvant therapy targeted at PML may be a promising therapeutic strategy for glioblastoma.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22542810 DOI: 10.1016/j.canlet.2012.04.013
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679